Zobrazeno 1 - 10
of 41
pro vyhledávání: '"I Moya-Carmona"'
Autor:
A. Padilla-Galo, A. J. García-Ruiz, R. Ch. Levy Abitbol, C. Olveira, F. Rivas-Ruiz, N. García-Agua Soler, M. Pérez Morales, B. Valencia Azcona, B. Tortajada-Goitia, I. Moya-Carmona, A. Levy-Naon
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-14 (2021)
Abstract Background Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems. The aim of this study was to evaluate clinical outcomes and healthcare expenditu
Externí odkaz:
https://doaj.org/article/98b3f7575b7a4d0e98a2aaaedd66576b
Autor:
A. Padilla-Galo, RCh Levy-Abitbol, C. Olveira, B. Valencia Azcona, M. Pérez Morales, F. Rivas-Ruiz, B. Tortajada-Goitia, I. Moya-Carmona, A. Levy-Naon
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone mar
Externí odkaz:
https://doaj.org/article/927ef4563ea249bf88ce7e5e4ab07d4e
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29e9087c2b0b91a50a5a6818406b042a
https://doi.org/10.1136/ejhpharm-2022-eahp.318
https://doi.org/10.1136/ejhpharm-2022-eahp.318
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3400255d345db4e3efd30551c2142e4
https://doi.org/10.1136/ejhpharm-2022-eahp.167
https://doi.org/10.1136/ejhpharm-2022-eahp.167
Autor:
B. Tortajada-Goitia, B. Valencia Azcona, R. Ch. Levy Abitbol, I. Moya-Carmona, Antonio García-Ruiz, A. Levy-Naon, M. Pérez Morales, N. García-Agua Soler, Alicia Padilla-Galo, Francisco Rivas-Ruiz, Casilda Olveira
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-14 (2021)
Respiratory Research
Respiratory Research
Background Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems. The aim of this study was to evaluate clinical outcomes and healthcare expenditure after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9094c5c466536476850bde62930f16d4
https://hdl.handle.net/10668/17842
https://hdl.handle.net/10668/17842
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Tocilizumab is an anti-human IL-6 receptor monoclonal antibody used in the treatment of cytokine release syndrome in patients with pneumonia associated with coronavirus disease. Despite the data from the COVACTA study, tocil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::293d45dd7615d4e118d3e225b2989e7a
https://doi.org/10.1136/ejhpharm-2021-eahpconf.170
https://doi.org/10.1136/ejhpharm-2021-eahpconf.170
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance Treatment goals for advanced or metastatic breast cancer include not only delaying progression of the disease and extending survival, but also maintaining or improving the quality of the patient’s life. New targeted therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d45592c1a2b0551071f3ffcde8297815
https://doi.org/10.1136/ejhpharm-2021-eahpconf.285
https://doi.org/10.1136/ejhpharm-2021-eahpconf.285
Autor:
M Sánchez-Argaiz, N Martinez-Casanova, E Sanchez-Yañez, I Moya-Carmona, F Gómez-Derueda, B Cancela-Díez
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance Immune checkpoint inhibitors (ICIs) represent a milestone therapy in many types of cancer, such as melanoma. Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody with antitumour activity in melanoma. Only a fe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6acd31ff5630921cb0ce5c585411230b
https://doi.org/10.1136/ejhpharm-2021-eahpconf.269
https://doi.org/10.1136/ejhpharm-2021-eahpconf.269
Autor:
Francisco Rivas-Ruiz, Casilda Olveira, Alicia Padilla-Galo, I. Moya-Carmona, B. Tortajada-Goitia, M. Pérez Morales, RCh Levy-Abitbol, A. Levy-Naon, B. Valencia Azcona
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-12 (2020)
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-12 (2020)
BackgroundBenralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Becau
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c74b440e70d86f9c3babc5660932cb91
https://doi.org/10.1186/s12890-020-01220-9
https://doi.org/10.1186/s12890-020-01220-9
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance One of the main factors that increases antibiotic pressure and contributes to the development of bacterial resistance is an increase in duration of antibiotic treatment. Strategies to reduce the duration of antibiotic treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9c75d16d6b0ef453747aae83c86c6ea
https://doi.org/10.1136/ejhpharm-2020-eahpconf.342
https://doi.org/10.1136/ejhpharm-2020-eahpconf.342